Literature DB >> 27260291

Cognition and eating behavior in amyotrophic lateral sclerosis: effect on survival.

R M Ahmed1,2,3,4, J Caga5, E Devenney5,6,7,8, S Hsieh5, L Bartley6, E Highton-Williamson5, E Ramsey5, M Zoing5, G M Halliday6,7, O Piguet6,7,8, J R Hodges6,7,8, M C Kiernan5.   

Abstract

It is increasingly recognized that metabolic factors influenced by eating behavior, may affect disease progression in neurodegeneration. In frontotemporal dementia (FTD), which shares a significant overlap with Amyotrophic lateral sclerosis (ALS), patients are well known to develop changes in eating behavior. Whether patients with pure ALS and those with cognitive and behavioral changes associated with ALS also develop similar changes is not known. The current study aimed to examine caloric intake, eating behavioral changes, body mass index, and using cox regression analyses survival across the spectrum of 118 ALS-FTD patients (29 pure ALS, 12 ALS-plus and 21 ALS-FTD, 56 behavioral variant FTD), compared with 25 control subjects. The current study found contrary to previous assumptions eating changes are not restricted to FTD, but a spectrum of eating behavioral changes occur in ALS, present in those with pure ALS and worsening as patients develop cognitive changes. ALS patients with cognitive impairment exhibited changes in food preference, with caloric intake and BMI increasing with the development of cognitive/behavioral changes. Both pure ALS and those with cognitive impairment demonstrated increased saturated fat intake. Survival analyses over the mean patient follow-up period of 6.9 years indicated that increasing eating behavioral changes were associated with an improved survival (threefold decrease risk of dying). Changes in eating behavior and metabolism occur in ALS in association with increasing cognitive impairment, perhaps exerting a protective survival influence. These changes provide insights into the common neural networks controlling eating and metabolism in FTD and ALS and provide potential targets to modify disease prognosis and progression.

Entities:  

Keywords:  Amyotrophic lateral sclerosis; Eating; Frontotemporal dementia; Hypothalamus; Metabolism; Neurodegeneration; Neuroendocrine

Mesh:

Year:  2016        PMID: 27260291     DOI: 10.1007/s00415-016-8168-2

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  62 in total

1.  High-caloric food supplements in the treatment of amyotrophic lateral sclerosis: a prospective interventional study.

Authors:  Johannes Dorst; Joschka Cypionka; Albert C Ludolph
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2013-08-14       Impact factor: 4.092

2.  Thiamine deficiency in amyotrophic lateral sclerosis.

Authors:  Sarah Jesse; Dietmar R Thal; Albert C Ludolph
Journal:  J Neurol Neurosurg Psychiatry       Date:  2015-04-21       Impact factor: 10.154

3.  Body mass index delineates ALS from FTD: implications for metabolic health.

Authors:  R M Ahmed; E Mioshi; J Caga; M Shibata; M Zoing; L Bartley; O Piguet; J R Hodges; M C Kiernan
Journal:  J Neurol       Date:  2014-06-24       Impact factor: 4.849

4.  EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)--revised report of an EFNS task force.

Authors:  Peter M Andersen; Sharon Abrahams; Gian D Borasio; Mamede de Carvalho; Adriano Chio; Philip Van Damme; Orla Hardiman; Katja Kollewe; Karen E Morrison; Susanne Petri; Pierre-Francois Pradat; Vincenzo Silani; Barbara Tomik; Maria Wasner; Markus Weber
Journal:  Eur J Neurol       Date:  2011-09-14       Impact factor: 6.089

5.  The overlap of amyotrophic lateral sclerosis and frontotemporal dementia.

Authors:  Catherine Lomen-Hoerth; Thomas Anderson; Bruce Miller
Journal:  Neurology       Date:  2002-10-08       Impact factor: 9.910

Review 6.  Amyotrophic lateral sclerosis--a model of corticofugal axonal spread.

Authors:  Heiko Braak; Johannes Brettschneider; Albert C Ludolph; Virginia M Lee; John Q Trojanowski; Kelly Del Tredici
Journal:  Nat Rev Neurol       Date:  2013-11-12       Impact factor: 42.937

Review 7.  Diagnosis and treatment of bulbar symptoms in amyotrophic lateral sclerosis.

Authors:  Peter Kühnlein; Hans-Jürgen Gdynia; Anne-Dorte Sperfeld; Beate Lindner-Pfleghar; Albert Christian Ludolph; Mario Prosiegel; Axel Riecker
Journal:  Nat Clin Pract Neurol       Date:  2008-06-17

Review 8.  Trials of antidiabetic drugs in amyotrophic lateral sclerosis: proceed with caution?

Authors:  Ali Jawaid; Sabrina Paganoni; Cecile Hauser; Paul E Schulz
Journal:  Neurodegener Dis       Date:  2013-10-02       Impact factor: 2.977

Review 9.  The syndromes of frontotemporal dysfunction in amyotrophic lateral sclerosis.

Authors:  Michael J Strong
Journal:  Amyotroph Lateral Scler       Date:  2008-12

10.  TDP-43 pathology in the basal forebrain and hypothalamus of patients with amyotrophic lateral sclerosis.

Authors:  Matthew D Cykowski; Hidehiro Takei; Paul E Schulz; Stanley H Appel; Suzanne Z Powell
Journal:  Acta Neuropathol Commun       Date:  2014-12-24       Impact factor: 7.801

View more
  16 in total

Review 1.  Physiological changes in neurodegeneration - mechanistic insights and clinical utility.

Authors:  Rebekah M Ahmed; Yazi D Ke; Steve Vucic; Lars M Ittner; William Seeley; John R Hodges; Olivier Piguet; Glenda Halliday; Matthew C Kiernan
Journal:  Nat Rev Neurol       Date:  2018-03-23       Impact factor: 42.937

Review 2.  Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria.

Authors:  Michael J Strong; Sharon Abrahams; Laura H Goldstein; Susan Woolley; Paula Mclaughlin; Julie Snowden; Eneida Mioshi; Angie Roberts-South; Michael Benatar; Tibor HortobáGyi; Jeffrey Rosenfeld; Vincenzo Silani; Paul G Ince; Martin R Turner
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2017-01-05       Impact factor: 4.092

Review 3.  Altered Bioenergetics and Metabolic Homeostasis in Amyotrophic Lateral Sclerosis.

Authors:  Andrew T Nelson; Davide Trotti
Journal:  Neurotherapeutics       Date:  2022-06-30       Impact factor: 6.088

4.  Prognostic significance of body weight variation after diagnosis in ALS: a single-centre prospective cohort study.

Authors:  Toshio Shimizu; Yuki Nakayama; Chiharu Matsuda; Michiko Haraguchi; Kota Bokuda; Kazuko Ishikawa-Takata; Akihiro Kawata; Eiji Isozaki
Journal:  J Neurol       Date:  2019-03-13       Impact factor: 4.849

Review 5.  Body mass index and survival from amyotrophic lateral sclerosis: A meta-analysis.

Authors:  Efthimios Dardiotis; Vasileios Siokas; Maria Sokratous; Zisis Tsouris; Athina-Maria Aloizou; Desponia Florou; Metaxia Dastamani; Alexios-Fotios A Mentis; Alexandros G Brotis
Journal:  Neurol Clin Pract       Date:  2018-10

Review 6.  Pathophysiology and Treatment of Non-motor Dysfunction in Amyotrophic Lateral Sclerosis.

Authors:  Colin J Mahoney; Rebekah M Ahmed; William Huynh; Sicong Tu; Jonathan D Rohrer; Richard S Bedlack; Orla Hardiman; Matthew C Kiernan
Journal:  CNS Drugs       Date:  2021-05-15       Impact factor: 5.749

Review 7.  Importance of lipids for upper motor neuron health and disease.

Authors:  Aksu Gunay; Heather H Shin; Oge Gozutok; Mukesh Gautam; P Hande Ozdinler
Journal:  Semin Cell Dev Biol       Date:  2020-12-13       Impact factor: 7.727

8.  Neural correlates of fat preference in frontotemporal dementia: translating insights from the obesity literature.

Authors:  Rebekah M Ahmed; Nga Yan Tse; Yu Chen; Elana Henning; John R Hodges; Matthew C Kiernan; Muireann Irish; I Sadaf Farooqi; Olivier Piguet
Journal:  Ann Clin Transl Neurol       Date:  2021-05-11       Impact factor: 4.511

Review 9.  Hypothalamic Alterations in Neurodegenerative Diseases and Their Relation to Abnormal Energy Metabolism.

Authors:  Pauline Vercruysse; Didier Vieau; David Blum; Åsa Petersén; Luc Dupuis
Journal:  Front Mol Neurosci       Date:  2018-01-19       Impact factor: 5.639

Review 10.  What is "Hyper" in the ALS Hypermetabolism?

Authors:  Alberto Ferri; Roberto Coccurello
Journal:  Mediators Inflamm       Date:  2017-09-07       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.